The Temple News highlighted phase 1 study results for KLS-13019, a cannabidiol-like molecule that has potential as a non-opioid alternative in the prevention and reversal of chemotherapy-induced neuropathic pain. Sara Jane Ward, PhD, Assistant Professor of Pharmacology at the Lewis Katz School of Medicine at Temple University, has been working with KannaLife Sciences, Inc., the biopharmaceutical company that patented KLS-13019, on the animal model portions of the research. She offered insight to the Temple News for their article on the subject.
Weather Alert: A major winter storm is likely to impact the Philadelphia region this weekend into Monday. Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH